

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval	
Afrezza® (insulin human) Inhalation Powder	T1 and T2 diabetes mellitus (adults)	Marketed					International Expansion: Brazil (Biommm) India (Cipla): In Process
Pediatric Afrezza® (insulin human) Inhalation Powder	Indication Expansion: T1 and T2 diabetes mellitus (pediatrics)	Phase 3					
V-Go® all-in-one insulin delivery patch	management of diabetes mellitus in persons requiring insulin (adults)	Marketed					
Tyvaso DPI® (treprostinil) Inhalation Powder <small>(marketed by United Therapeutics)</small>	pulmonary arterial hypertension / pulmonary hypertension associated with interstitial lung disease	Marketed					
Clofazimine Inhalation Suspension (MNKD-101)	nontuberculous mycobacterial lung disease	Phase 3					
Nintedanib DPI (MNKD-201)	idiopathic pulmonary fibrosis	Phase 1					
Dornase Alfa (MNKD-301)	cystic fibrosis	Preclinical					

